Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy
S. P. Treon
, Y. Shima
, F. I. Preffer
, D. S. Doss
, L. Ellman
, R. L. Schlossman
, M. L. Grossbard
, A. R. Belch
, L. M. Pilarski
, K. C. Anderson
Research output
:
Contribution to journal
›
Article
›
peer-review
49
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Myeloma
100%
Antibody-mediated
100%
CD20
100%
Plasma Cells
100%
Plasma Cell Dyscrasia
100%
Serotherapy
83%
Waldenström Macroglobulinemia
66%
Interferon-α (IFN-α)
50%
B Cells
50%
Rituximab
50%
CD20 Expression
50%
Bone Marrow
33%
Cell-to-cell
33%
CD20+
33%
Patient Plasma
33%
Rituximab Therapy
33%
Multiple Myeloma Patients
33%
Anti-CD20 Antibody
33%
Anemia
16%
Therapeutic Monoclonal Antibody
16%
Inducer
16%
San Diego
16%
Myeloma Cells
16%
Flow Cytometric Analysis
16%
Tumor Cells
16%
CD54
16%
CD38
16%
Phase II Trial
16%
Peripheral Blood
16%
CD19
16%
Immunoglobulin
16%
Strategies to Overcome
16%
San Francisco
16%
Rituxan
16%
Genentech
16%
Paraprotein
16%
Core Protein
16%
Idiotype
16%
Anti-CD20
16%
B-cell Malignancies
16%
HM1.24
16%
Ricin Toxin
16%
Anti-CD19 Monoclonal Antibody
16%
I-core
16%
Immunology and Microbiology
Immunotherapy
100%
CD20
100%
Plasma Cell Dyscrasia
100%
Multiple Myeloma
66%
Rituximab
66%
Immunoglobulin Producing Cell
50%
B Cell
33%
Macroglobulinemia
33%
interferon
25%
CD19
16%
Monoclonal Antibody
8%
Myeloma Cell
8%
Tumor Cell
8%
CD38
8%
Myeloma Protein
8%
Idiotype
8%
Monoclonal Antibody Therapy
8%
Ricin
8%
Susceptibility
8%
Medicine and Dentistry
Immunotherapy
100%
CD20
100%
Plasma Cell Dyscrasia
100%
Multiple Myeloma
66%
Rituximab
66%
Immunoglobulin Producing Cell
50%
B Cell
33%
Waldenström's Macroglobulinemia
33%
Interferon
25%
Anemia
8%
Monoclonal Antibody Therapy
8%
Monoclonal Antibody
8%
Cancer
8%
Myeloma Cell
8%
Tumor Cell
8%
Phase II Trials
8%
Paraprotein
8%
Immunoglobulin Idiotype
8%
Core Protein
8%
Ricin
8%